Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza

By Cure SMA | Published On January 13, 2017

Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza

With the news today that the first-ever patient has received the first commercial Spinraza dose, we are releasing an updated version of our SMA drug pipeline. This new version reflects the approval of Spinraza, as well as the true start of a key stage to ensure that more and more patients are able to gain access to Spinraza.

We are excited that patients are now gaining real commercial access to this first-ever approved therapy for SMA, and know that more work remains to ensure the treatment is broadly available as quickly as possible.

“We are very encouraged that individuals with SMA have already started treatment with Spinraza this week in the U.S., and we continue to work closely with regulatory agencies to bring this therapy to patients around the world as quickly as possible,” said Wildon Farwell, MD, MPH, senior medical director, Clinical Development, Biogen.

More About the Implementation of Access to Spinraza

We are currently building a list of centers that will be administering Spinraza, including center name, address, and key contact(s) for each site. We expect to release the first version in the next few weeks, and will be continually updating as more sites are added.

If you or your child attend a clinic or center that will be administering Spinraza, or if the clinic or center is considering becoming a Spinraza site, please ask them to reach out to us at patientcare@curesma.org.

In addition, we have posted a recording of last week’s Spinraza Approval Webinar, for those who were not able to attend. You can view the recording on our YouTube channel.

Please visit our Spinraza page for links to these and other important resources.

Topics: Community & Awareness, Advocacy, Front Page News

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software